T6126

JNJ-7706621 is a potent aurora kinase inhibitor that also inhibits CDK1 and CDK2.

Vutiglabridin (HSG4112) is a novel and safe modulator of PON2, a racemic compound. vutiglabridin is an optimized structural analogue of Glabridin and is superior to Glabridin in terms of weight loss and chemical stability. vutiglabridin ameliorates mptp-induced neurodegeneration in Parkinson's disease mice by targeting mitochondrial paraoxonase-2. Vutiglabridin is a clinical phase 2 drug for the treatment of obesity and has therapeutic effects on p-mitochondrial PON2 in a PD model. vutiglabridin penetrates the brain, binds PON2, and restores 1-methyl-4-phenylpyridine (MPP*)-induced neuroblastoma in SH-SY5Y Vutiglabridin significantly attenuated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dyskinesia and dopaminergic neuronal damage in mice modeled with PD in mouse experiments.

Ruzotolimod (RO7020531) is an orally active Toll-like receptor 7 agonist that suppresses WHV replication and, in combination with RO-7049389, significantly reduces AAV-HBV viral load, while also serving as an experimental immunomodulatory agent for studying antiviral innate immune responses and therapeutic strategies relevant to SARS-CoV-2 and COVID-19 infection models.

Isofezolac (LM 22070) is a non-steroidal anti-inflammatory drug (NSAID) known for its potent inhibition of prostaglandin-synthetase, exhibiting significant anti-inflammatory and antipyretic properties [1] [2].

ZLD2218, a potent inhibitor of BRD4 with an IC50 value of 107 nM, has been demonstrated to mitigate kidney injury and fibrosis through extensive studies.

COX-2-IN-19 (Compound 24) is a highly potent cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 1.76 μM, exhibiting significant in vivo anti-inflammatory activity [1].

Exo2 is a secretion inhibitor that cell-specifically disrupts the integrity of the trans-Golgi network (TGN) and interferes with the delivery of Shiga toxin to the endoplasmic lumen, and can be used to examine membrane trafficking in mammalian cells.

CA224 (Compound 1), an orally active and selective Cdk4–cyclin D1 inhibitor, demonstrates an IC50 of 6.2 µM. It induces cell apoptosis and exhibits antitumor activity [1].

EGFR-IN-68 (Compound 8d) is a potent EGFR inhibitor with an IC50 value of 0.33 μM and exhibits notable anticancer properties [1].

Anti-osteoporosis agent-1 (comp 4aa) is a potent RPA (replication protein A) inhibitor with an IC50 value of 18 μM [1].